SciELO - Scientific Electronic Library Online

 
vol.24 número4Pulmonary hypertension of the newborn with in utero closure of the ductus arteriosus and twin reversed arterial perfusion sequence índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Colombiana de Cardiología

versão impressa ISSN 0120-5633

Resumo

WILLS-SANIN, Beatriz; RINCON, Alejandra; MONTENEGRO, Ana Cristina  e  BUITRAGO-SANDOVAL, Andrés F.. Proprotein convertase subtilisin/kexin type 9 inhibitors: an alternative for treating dyslipidemias. Rev. Colomb. Cardiol. [online]. 2017, vol.24, n.4, pp.411-416.  Epub 16-Fev-2017. ISSN 0120-5633.  https://doi.org/10.1016/j.rccar.2016.11.002.

International clinical practice guidelines recommend statins as the treatment of choice for managing dyslipidemias. However, despite evidence regarding the importance of controlling this condition, there is a significant percentage of adults who do not meet their target lipids with statins. This has stimulated the development of monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9. These drugs have been approved as adjuvants for the diet and the maximum tolerated statin dosage in familial hypercholesterolemia or clinical atherosclerosis in patients requiring an additional reduction of low-density lipoproteins. This article reviews current evidence regarding antibodies against proprotein convertase subtilisin/kexin type 9 with the goal of optimising clinical treatment of our patients.

Palavras-chave : Hypercholesterolemia; Pharmacology; LDL cholesterol; Antibodies.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )